$-0.57 EPS Expected for Sarepta Therapeutics, Inc. (SRPT)

June 15, 2018 - By Sophie Menendez

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) LogoInvestors sentiment decreased to 0.97 in Q1 2018. Its down 0.25, from 1.22 in 2017Q4. It is negative, as 31 investors sold Sarepta Therapeutics, Inc. shares while 81 reduced holdings. 45 funds opened positions while 64 raised stakes. 54.74 million shares or 3.52% more from 52.88 million shares in 2017Q4 were reported.
Hikari Power Ltd accumulated 25,000 shares or 0.22% of the stock. 145,145 are held by Fuller And Thaler Asset Management. Wellington Management Gru Llp has 15,981 shares for 0% of their portfolio. Orbimed Advsrs Ltd reported 321,600 shares stake. Prudential Fincl invested in 0.01% or 53,215 shares. Barclays Public Limited Company accumulated 45,639 shares. Janney Montgomery Scott Limited Liability Corp holds 6,920 shares. Advisers Ltd Liability Co has 26,111 shares. Century Companies owns 63,009 shares. Stonebridge Capital Mgmt invested 0.08% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Sg Americas Securities Llc, a New York-based fund reported 4,386 shares. Dupont Cap Corp reported 0.01% stake. California-based Schwab Charles Investment Mngmt has invested 0.02% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Driehaus Mgmt Limited Liability Com reported 0.14% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Blair William Comm Il has 33,575 shares.

Analysts expect Sarepta Therapeutics, Inc. (NASDAQ:SRPT) to report $-0.57 EPS on July, 18.They anticipate $0.58 EPS change or 50.43 % from last quarter’s $-1.15 EPS. After having $-0.44 EPS previously, Sarepta Therapeutics, Inc.’s analysts see 29.55 % EPS growth. The stock increased 2.08% or $2.01 during the last trading session, reaching $98.78. About 1.65 million shares traded or 32.02% up from the average. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has risen 197.08% since June 15, 2017 and is uptrending. It has outperformed by 184.51% the S&P500.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Ratings Coverage

Among 16 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 14 have Buy rating, 0 Sell and 2 Hold. Therefore 88% are positive. Sarepta Therapeutics had 27 analyst reports since January 3, 2018 according to SRatingsIntel. As per Monday, January 22, the company rating was initiated by RBC Capital Markets. Janney Capital initiated Sarepta Therapeutics, Inc. (NASDAQ:SRPT) on Wednesday, January 3 with “Buy” rating. Credit Suisse maintained the stock with “Outperform” rating in Friday, May 4 report. The company was maintained on Friday, February 9 by Piper Jaffray. The firm earned “Buy” rating on Friday, March 2 by Piper Jaffray. The firm earned “Overweight” rating on Wednesday, February 21 by JP Morgan. As per Tuesday, March 13, the company rating was maintained by Leerink Swann. The company was upgraded on Friday, May 11 by Barclays Capital. The company was maintained on Wednesday, March 14 by JP Morgan. On Monday, March 12 the stock rating was maintained by H.C. Wainwright with “Buy”.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA therapeutics for the treatment of rare neuromuscular diseases. The company has market cap of $6.47 billion. The firm offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy , which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It currently has negative earnings. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD.

More notable recent Sarepta Therapeutics, Inc. (NASDAQ:SRPT) news were published by: Investorplace.com which released: “7 Strong Buy Stocks Analysts Are Upgrading Now, Including Facebook, Inc.” on June 13, 2018, also Nasdaq.com with their article: “Biotech ETFs Are the Best Way to Play the Recovering Sector” published on May 30, 2018, Seekingalpha.com published: “EMA’s advisory committee thumbs down on Sarepta’s Exondys” on June 01, 2018. More interesting news about Sarepta Therapeutics, Inc. (NASDAQ:SRPT) were released by: Streetinsider.com and their article: “Sarepta Therapeutics (SRPT) Announces Long-term Strategic Manufacturing Partnership with Brammer Bio” published on June 13, 2018 as well as Nasdaq.com‘s news article titled: “Sarepta Therapeutics Enters into Long-term Strategic Manufacturing Partnership with Brammer Bio to Support Gene …” with publication date: June 13, 2018.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.